JPM cuts Essity to “underweight” as soaring pulp, energy costs sour outlook

J.P. Morgan downgraded Essity AB to underweight from neutral and cut its December 2027 price target to Skr215 from Skr245, citing accelerating energy and pulp cost inflation. The broker now sees FY26 adjusted EBITA margin at 13.1% versus 13.8% consensus and adjusted EPS at Skr4.02 versus Skr4.42 consensus, while forecast 2026 adjusted EPS was cut 4.2% to Skr17.46. Upside is limited to better-than-expected demand/pricing and a weaker U.S. dollar.

Analysis

The market is likely underestimating how asymmetric this setup is for the sector: margin pressure from inputs hits immediately, while pricing relief is slower and less certain, so earnings revisions can continue for several quarters even if volumes hold up. That creates a classic multiple-compression risk for consumer staples that screen as defensive but are actually levered to two volatile commodities—energy and pulp—right when hedging rolls off. The key second-order effect is that competitors with better self-help, lighter pulp exposure, or stronger emerging-market mix can gain share as the company tries to defend price in a softer category backdrop.

The biggest catalyst window is Q2 through H2, when the hedge cushion fades and the full cost stack starts to show up in reported margins. If management leans on price to offset inflation, the risk is volume elasticity and trade-down into private label, especially in tissue and other highly substitutable lines; if they absorb cost, EPS downgrades can still continue into the next estimates reset. Either path is bad near term unless the USD weakens materially, because that would mechanically ease import-linked cost pressure and could stabilize consensus sooner than volume recovery.

The contrarian read is that the stock may not be cheap enough for a cyclical margin drawdown disguised as a quality compounder. A move lower in the share price could be the start of a multi-quarter derating rather than a one-off reaction, because the earnings bridge is being revised down while the market still pays a mid-teens multiple. That said, if pricing proves stickier than expected in the first half and commodity inflation peaks earlier than modeled, the stock can re-rate sharply off a low-growth base; the setup is a timing trade, not a structural short thesis.

Key Decisions for Investors

• Short ESSITYB / buy back after Q1 print if pricing remains weak: 3-6 month horizon, targeting a further 8-12% downside as margin revisions catch up; stop if management guides to positive pricing inflection or confirms H2 cost relief.
• Pair trade: long low-input-cost European defensives, short ESSITYB over the next 1-2 quarters. Best expression is long a name with stronger pricing power and less pulp exposure versus ESSITYB to isolate commodity-margin compression.
• Buy short-dated put spreads on ESSITYB into the next earnings cycle (2-4 months): structure for a 2:1 to 3:1 payoff if the market starts discounting the H2 margin peak before consensus cuts are complete.
• For fundamental longs, wait for a post-Q2 setup rather than catching the knife now: only consider entry if the stock de-rates another 10%+ and management validates cost peak timing, which would improve risk/reward materially.